为撒哈拉以南非洲地区推进瘤学药物治疗
Kirthana Sharma1,2, Tina Mayer3, Sharon Li4
1Rutgers Global Health Institute, New Brunswick, New Jersey, United States of America.
PLOS global public health
|June 27, 2023
概括
撒哈拉以南非洲的癌症发病率正在上升,对必要的瘤药物和临床试验的获取有限. 解决成本,基础设施和人员差距对于改善癌症治疗和生存率至关重要.
科学领域:
- 在瘤学瘤学.
- 全球健康 全球健康
- 药物经济学 药物经济学
背景情况:
- 撒哈拉以南非洲 (SSA) 的癌症发病率正在增加,通常在晚期呈现,生存结果不佳.
- 与高收入国家相比,SSA在获得先进的瘤治疗方法方面的差异仍然存在.
- 挑战包括高药费用,基础设施不足和训练有素的医疗保健专业人员短缺.
研究的目的:
- 审查选择的瘤药物疗法,对SSA中常见的恶性瘤有潜在的益处.
- 突出世界卫生组织基本药物模型清单上药物获取的重要性.
- 为了确定SSA地区内瘤学临床试验获取的差距.
主要方法:
- 来自高收入国家的开创性临床试验的文献综述.
- 对瘤学药物获取挑战的分析,具体针对SSA.
- 在SSA地区可用的瘤学临床试验的表格.
主要成果:
- 选择的瘤治疗药物显示出改善SSA癌症结局的潜力.
- 在获得必需的瘤药物和临床试验方面,在SSA之间存在显著的差异.
- 药物获取的主要障碍包括成本,基础设施和劳动力限制.
结论:
- 迫切需要采取行动,通过改善获得瘤药物和临床试验的机会,应对南亚地区不断增长的癌症负担.
- 解决系统性挑战对于改善该地区的癌症护理和患者存活率至关重要.
- 确保获得基本药物和扩大临床试验参与是重要的步骤.
相关概念视频
Cancer Therapies
7.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.8K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Combination Therapies and Personalized Medicine
5.0K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Tumor Immunotherapy
575
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
575
Cancer Survival Analysis
402
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
402


